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Abstract
We developed a new system for light-induced protein dimerization in living cells using a novel
photocaged analog of rapamycin (pRap) together with an engineered rapamycin binding domain
(iFKBP). Using focal adhesion kinase as a target, we demonstrated successful light-mediated
regulation of protein interaction and localization in living cells. Modification of this approach
enabled light-triggered activation of a protein kinase and initiation of kinase-induced phenotypic
changes in vivo.
Rapamycin (Rap, Figure 1a), also known as sirolimus, is a complex macrolide natural
product isolated from the bacterium Streptomyces hygroscopicus, found in a soil sample on
Easter Island in 1975.1–4 Rapamycin mediates heterodimerization of the proteins FKBP12
(FK506 binding protein 12) and FRB (FKBP12 rapamycin binding domain).1 Due to
rapamycin’s excellent physiological properties, including good pharmacokinetics,
permeability across the blood-brain barrier, and oral bioavailability,2 it has been used as a
small molecule dimerizer for a wide range of applications in mammalian cells and
organisms.3 Furthermore, the FRB-FKBP12 interaction has proven valuable in a broad
range of basic research applications, where it has been engineered to control gene function
through rapamycin-induced transcription,4, 5 protein localization,4 protein degradation,6
and DNA recombination.7 We recently showed that rapamycin can control kinase activity
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when an engineered version of FKBP is inserted at a conserved position in the kinase active
site8. Thus, a photo-activatable analog of rapamycin represents a unique and important
biological research tool, enabling the regulation of heterodimerization and kinase activity
using light as a noninvasive regulatory element that can be controlled with high spatial and
temporal resolution.
Photo-activatable derivatives of small molecules are typically generated through the
installation of a light-removable protecting group, a so called “caging group”, at a site
crucial for biological activity of the small molecule.9 This renders the molecule inactive,
until the caging group is removed through light-irradiation, typically with UV light of 365–
405 nm.10 The feasibility of this approach has been demonstrated through successful
photochemical regulation of numerous small molecules in cellular environments and
multicellular organisms.9, 11 Here, we report the synthesis of a photocaged rapamycin
analog (pRap, Figure 1a) which, together with an engineered FKBP (iFKBP), enables
successful photo-control of the FKBP-FRB interaction (Figure 1b). The caged rapamycin is
applied to regulate both protein dimerization and kinase activity in live cells. Interestingly,
caging is not effective with unaltered FKBP, but requires the FKBP mutations described
here. An analysis of the chemically accessible sites of rapamycin (Rap) revealed that the
methoxy group on C-16 can undergo nucleophilic substitution13–17 and β-elimination.12
The hydroxyl groups at C-28 and C-40 can be protected with silyl groups,13,14 and a
trifluoromethylsulfonyl group.15 The lactone at C-34 can be hydrolyzed and eliminated22–24
and, importantly, the hydroxyl group at C-40 can be converted into a carbonate group15 and
be esterified.15, 20, 21 Thus, C-40 represents the most suitable site for chemical modification
with a carbonate-linked caging group that can provide facile installation and quick
photolysis. Importantly, based on the crystal structure of the ternary complex of rapamycin,
FRB, and FKBP12, the hydroxyl group at C-40 undergoes hydrogen bond formation with
the glutamine 53 of FKBP12 (Figure 1c).16 Thus, we hypothesized that disruption of that
hydrogen bond through installation of a sterically demanding α-methyl-6-
nitropiperonyloxycarbonyl (MeNPOC) group would prevent protein dimerization.
The caged rapamycin pRap was synthesized in one step from rapamycin (Rap) via
chemoselective acylation with the mixed carbonate of 6-nitro-piperonyl alcohol and N-
hydroxysuccinimide (NPOC-NHS, Figure 1a). The identity of purified pRap was confirmed
by 1H NMR and HRMS analysis (see Supporting Information).
We first tested whether pRap could induce dimerization of FKBP12 and FRB. For this we
created a GFP-FRB protein fusion and wild-type FKBP12 fused to the N-terminus of focal
adhesion kinase (FAK). FAK localizes prominently to focal adhesions in living cells,17
allowing us to test dimerization in vivo by observing rapamycin-mediated translocation of
GFP-FRB into focal adhesions. Prior to live cell co-localization studies, the constructs were
tested in pull-down assays, comparing the ability of pRap and Rap to mediate the
intracellular dimerization of FKBP-FAK and FRB. Cells expressing both FKBP-FAK and
FRB were treated with rapamycin or pRap for one hour, with or without irradiation.
Complex formation was assayed by pulling down myc-FKBP-FAK from cell lysates and
blotting for GFP-FRB (Supporting Figure 1a, b). Surprisingly, both small molecules
generated dimerization with similar effectiveness, with or without UV irradiation
(Supporting Figure 1a, b). These results were further confirmed by an mTOR activity assay
(Supporting Figure 2). This data showed that the FKBP12-rapamycin-FRB complex was not
sufficiently sensitive to rapamycin modification for a successful light-activation approach
through photocaging.
We hypothesized that alteration of FKBP12 could be used to render the ternary rapamycin-
FKBP-FRB interaction more sensitive to the functional groups of pRap affected by
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photolysis. We tested a recently developed modified FKBP, named iFKBP, that is proposed
to have increased structural mobility of the Lys52-Glu54 loop positioned next to the C-40
hydroxyl group of rapamycin (Figure 1c).8 Using both an N-terminal iFKBP-FAK fusion
(as tested above for FKBP) and a fusion of iFKBP internally, at position 413 of FAK (Figure
2a), we examined whether pRap could mediate heterodimerization of iFKBP and FRB in a
light dependent manner. Indeed, pRap (at concentrations of up to 20 µM) failed to mediate
interaction between iFKBP-FAK and GFP-FRB, while irradiation of pRap-treated cells with
365 nm UV light successfully removed the caging group and induced iFKBP-FRB
dimerization (Figure 2b–d). Uncaging kinetics were dependent on both light dosage and
pRap concentration. Importantly, in the presence of pRap, translocation of FRB into focal
adhesions was observed only upon decaging, indicating successful protein dimerization
between FAK-iFKBP and FRB in live cells (Figure 2e–f). These studies demonstrated that
pRap can effectively mediate light-dependent protein heterodimerization when used with
iFKBP rather than FKBP12.
Recently, we developed a new method for the regulation of protein kinases in live cells.8
Insertion of iFKBP at a structurally conserved position within the catalytic domain of
several kinases, including FAK, rendered the kinases inactive. Our previous studies indicate
that insertion of the iFKBP increases the mobility of the critical G-loop in the catalytic
domain of FAK, resulting in the inhibition of catalytic activity.8 Formation of iFKBP-
rapamycin-FRB complex through addition of rapamycin significantly restricts iFKBP
dynamics, thus stabilizing the G-loop and rescuing the kinase activity.8 This was used to
achieve specific control of kinases in living cells with high temporal resolution.8
Here we tested the light-mediated regulation of FAK activity with pRap using RapR-FAK
(rapamycin-regulated FAK) as a model (Figure 3a). Myc-tagged RapR-FAK was co-
expressed with GFP-FRB in HEK293T cells. As in the published validation of RapR-FAK,
we examined rapamycin’s ability to induce RapR-FAK phosphorylation of the N-terminal
fragment of paxillin,18 a signal transduction adaptor protein and natural FAK substrate.
Unlike rapamycin, pRap was completely inactive at concentrations of up to 20 µM,
producing no detectable paxillin Tyr31 phosphorylation. UV irradiation alone did not
activate RapR-FAK in the absence of pRap, but irradiation in the presence of pRap (1–20
µM) induced activation of RapR-FAK through protein complex formation with FRB (Figure
3b), leading to robust phosphorylation of paxillin. Light-mediated interaction between
RapR-FAK and GFP-FRB was further confirmed by co-immunoprecipitation of the two
proteins (Figure 3b) and by translocation of FRB to focal adhesions (Figure 2f) upon pRap
irradiation.
Finally, we examined whether light induced activation of pRap could be used to control cell
behavior. FAK activation has been shown to produce large dorsal membrane ruffles8. We
therefore examined effects of RapR-FAK activation on the membrane dynamics of HeLa
cells. In the presence of pRap, but without UV irradiation, transfected HeLa cells displayed
normal, small peripheral ruffles around the border of the cell (Figure 3c), consistent with
inactive RapR-FAK. In contrast, UV irradiation (365 nm) produced very large and dynamic
ruffles across the dorsal cell surface (Figure 3d and Supporting Movie 1). This UV-induced
phenotype was displayed in 40% of analyzed cells (9 of 22 cells), in excellent agreement
with effects of regular rapamycin on RapR-FAK (56% positive cells).8
To explore how modification of FKBP to iFKBP was able to render pRap inactive until
irradiated with UV light, we performed discrete molecular dynamics (DMD) simulations.19
Within the sampled conformations we identified the dominant ensemble and compared the
localization of residues that form the iFKBP-FRB and FKBP12-FRB interfaces.
Surprisingly, our simulations demonstrated that binding of the caged rapamycin to iFKBP is
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at least as strong as that to FKBP12, but the interaction of the added piperonyloxycarbonyl
moiety with iFKBP distorts the protein’s binding-competent conformations and prevents
binding of FRB. The most notable difference between the iFKBP and FKBP complexes is a
significant distortion of the FRB-binding interface formed by the segment Asp41-Leu49
(Figure 4a–b; Supporting Movies 2–5). The interface area formed between pRap and iFKBP
is larger than that between pRap and FKBP12. Due to its higher structural plasticity, the
iFKBP protein is able to deform and create additional contacts with pRap, which is
unachievable by the more rigid and stable FKBP12. Based on these simulations, we suggest
that strong binding between iFKBP and pRap distorts the FRB-binding interface in
FKBP12, and thus prevents further binding to FRB.
In summary, we have developed a new photocaged analog of rapamycin, pRap, which can
be used together with iFKBP, an engineered version of FKBP12, for the light-mediated
regulation of protein dimerization. We demonstrated successful use of this new dimerization
system by modulating protein interactions for two different FAK-iFKBP fusions in living
cells. Furthermore, we achieved light-mediated activation of an engineered protein kinase,
FAK, and demonstrated light-induced changes in cell behavior characteristic of this kinase.
Rapamycin-mediated protein dimerization and regulation of kinases have lacked the precise
spatial and temporal control of light-mediated processes. Our new caged rapamycin
approach will significantly enhance the many existing methodologies that use rapamycin for
the regulation of protein activity in cells and multicellular organisms. We are currently
exploring the synthesis of caged, orthogonal rapalogs and two-photon activated caged
rapamycin.
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Photocaging of rapamycin. (a) Structure of rapamycin (Rap) and its synthetic
transformation into caged rapamycin (pRap) through selective acylation of the C-40
hydroxyl group with nitro-piperonyloxycarbonyl N-hydroxysuccinimide carbonate (NPOC-
NHS). (b) Schematic of the light-induced heterodimerization of the proteins FRB and
iFKBP using pRap. (c) Crystal structure of the ternary complex between rapamycin,
FKBP12 (green), and FRB (blue). The 2.65 Å hydrogen bond (possibly mediated through a
water molecule) between Gln53 of FKBP12 and the C-40 hydroxyl group of rapamycin is
indicated. PDB 2FAP.
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Light-regulated dimerization of iFKBP and FRB. (a) Positions of iFKBP insertions into
FAK. (b–d) HEK293T cells co-transfected with GFP-FRB and either myc-iFKBP-FAK (b,
c) or myc-FAK-iFKBP413 (d) were treated with either rapamycin (0.5 µM) or the indicated
concentrations of pRap. Ten minutes after addition of pRap or Rap, cells were irradiated
with 365 nm UV light for 1 min (b, d) or 5 min (c), and incubated for 1 hour. Control cells
were not irradiated. Myc-iFKBP-FAK was immunoprecipitated from cell lysates using anti-
myc antibody and co-immunoprecipitation of GFP-FRB was detected by Western Blot using
anti-GFP antibody. (e) HeLa cells co-transfected with GFP-FAK-iFKBP413 and mCherry-
FRB were treated with pRap (20 µM) for 30 min, followed by UV irradiation (365 nm, 2
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min). TIRF images were taken before and after irradiation. (f) HeLa cells co-transfected
with GFP-RapR-FAK and mCherry-FRB were treated with pRap (5 µM) for 30 min,
followed by UV irradiation (365 nm, 2 min). TIRF images were taken before and after
irradiation.
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Light-mediated activation of a protein kinase. (a) Schematic of RapR-FAK regulation by
pRap. (b) Myc-RapR-FAK kinase was co-expressed with GFP-FRB in HEK293T cells.
Cells were treated with the indicated amount of rapamycin (Rap), caged rapamycin (pRap),
or DMSO (control). The indicated samples were exposed to UV light (365 nm, 1 min). All
cells were incubated at 37 °C for 1 hour after treatment. Myc-RapR-FAK was
immunoprecipitated using an anti-myc antibody and tested in a kinase assay using an N-
terminal fragment of paxillin as a substrate. The level of phosphorylation of paxillin on
Tyr31 (probed with anti-phospho-Tyr31 paxillin antibody) indicates the kinase activity. (c,
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d) HeLa cells co-transfected with GFP-RapR-FAK and Cherry-FRB were treated with pRap
(1 µM) and imaged before (c) and after (d) UV irradiation (365 nm, 1 min). Arrows indicate
formation of large dorsal ruffles stimulated by activated RapR-FAK.
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Molecular dynamics simulations of the FKBP12-pRap-iFKBP interaction. (a) Tube
representations of FKBP12 (left) and iFKBP (right) with pRap in the binding pocket.
Warmer colors and thicker backbones correspond to fluctuations within the structure. Note
the greater mobility of iFKBP. (b) Binding interfaces of the pRap, FRB, and FKBP12 or
iFKBP complexes. For iFKBP (right) the interface area is reduced due to loss of contacts
between the Asp41-Leu49 segment and FRB. In the iFKBP complex, residues that were in
contact for the FKBP12 complex are marked in light brown. The segment deleted from
FKBP12 to produce iFKBP is marked with dark color in FKBP12.
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